Abiomed Inc. said late Monday it expects third-quarter revenue that is higher than the Wall Street consensus estimate. The medical device company said it sees preliminary third-quarter revenue of $85.8 million, a 38% increase from the year-ago quarter. Analysts surveyed by FactSet had forecast revenue of $78.9 million. Shares of Abiomed were flat at $85 in after-hours trading.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.